Triglycerides
Also known as: Hypertriglyceridemia
Methodology & AI Transparency ⓘ
Triglycerides Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are triglycerides? Triglycerides are a type of fat.
- 2 Real-world patient consensus: Clinical coding for Triglycerides uses ICD-10 E78.1 across Cholesterol & Lipids specialty care.
- 3 Typical cash cost range: Primary evaluation for Triglycerides incorporates nuclear magnetic resonance in Triglycerides (E78.1: (NMR) lipoprotein particle) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Triglycerides: maintaining Lipoprotein(a) [Lp(a)] [Triglycerides E78.1] within < 75 nmol/L (E78.1).
Ask our AI Specialists anything about Triglycerides
What Is Triglycerides?
What are triglycerides? Triglycerides are a type of fat. They are the most common type of fat in your body. They come from foods, especially butter, oils, and other fats you eat. Triglycerides also come from extra calories. These are the calories that you eat, but your body does not need right away. Your body changes these extra calories into triglycerides and stores them in fat cells. When your body needs energy, it releases the triglycerides. Your VLDL cholesterol particles carry the triglycerides to your tissues. Having a high level of triglycerides can raise your risk of heart diseases , such as coronary artery disease .
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Triglycerides (code E78.1) is remnant cholesterol accumulation [Triglycerides E78.1], Cross-referenced with NIH MeSH (Hypertriglyceridemia), which Cholesterol, Triglycerides & Lipids clinicians address while surveilling Lipoprotein(a) [Lp(a)] [Triglycerides E78.1] (< 75 nmol/L (E78.1)).
Common Symptoms & Clinical Signs
- • Regularly eating more calories than you burn off, especially if you eat a lot of sugar
- • Being overweight or having obesity
- • Presentation of Triglycerides (E78.1): achilles tendon thickening, in Triglycerides (E78.1: xanthelasma, or premature)
- • Secondary Triglycerides clinical sign: coronary artery calcium [Triglycerides E78.1]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Triglycerides Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E78.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cholesterol, Triglycerides & Lipids | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Lipoprotein(a) [Lp(a)] [Triglycerides E78.1] | < 75 nmol/L (E78.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Triglycerides E78.1] | < 70 mg/dL (< 55 mg/dL high risk) (E78.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: LDL Cholesterol [Triglycerides E78.1] | < 85 mg/dL (E78.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Triglycerides
Treatment selection for Triglycerides depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Triglycerides)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed high: What a 1,148-Participant Study Found The significant reductions of atherogenic lipids including LDL-C, non-HDL-C, and apolipoprotein B seen with evolocumab are similar in patients with and without mixed high cholesterol. Cardiovascular drugs and therapy • 2016-06-15 • Phase III Randomized Trial | N = 1,148 | 96/100 | PMID 27240673 ↗ |
| New Insights on Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus: What a 2,959-Participant Study Found Ezetimibe/simvastatin was more effective than rosuvastatin in LDL-C lowering, and provided greater or comparable improvements in other lipid measures and hsCRP at the approved usual starting, next highest, and maximum doses in... Current medical research and opinion • 2006-10-15 • Randomized Controlled Trial | N = 2,959 | 96/100 | PMID 17022864 ↗ |
| New Insights on Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin: What a 2,067-Participant Study Found Evolocumab reduced LDL-C levels by 66% (95% CI, 58% to 73%) to 75% (95% CI, 65% to 84%) (every 2 weeks) and by 63% (95% CI, 54% to 71%) to 75% (95% CI, 67% to 83%) (monthly) vs placebo at the mean of weeks 10 and 12 in the... JAMA • 2014-05-14 • Phase III Randomized Trial | N = 2,067 | 96/100 | PMID 24825642 ↗ |
| New Insights on Benefits and safety of ezetimibe coadministered with lovastatin in primary high: What a 548-Participant Study Found Ezetimibe plus lovastatin was well tolerated, with a safety profile similar to both lovastatin alone and placebo. The American journal of cardiology • 2003-02-15 • Randomized Controlled Trial | N = 548 | 93/100 | PMID 12586255 ↗ |
| New Insights on Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in: What a 259-Participant Study Found Tirzepatide reduces body weight and improves blood sugar control and uniquely modulates metabolites associated with T2D risk and metabolic dysregulation in a direction consistent with improved metabolic health. The Journal of clinical endocrinology and metabolism • 2022-01-18 • Randomized Controlled Trial | N = 259 | 93/100 | PMID 34608929 ↗ |
Triglycerides Patient Community & “People Like Me” Threads
Filter Triglycerides community threads and patient logs by age, biological sex, dosage, and treatment duration.